Herlyn M - Search Results

1

A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas.

Yu S, Wei S, Savani M, Lin X, Du K, Mender I, Siteni S, Vasilopoulos T, Reitman ZJ, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, Charbonneau CM, Sugarman E, Bowie M, Hariharan S, Waitkus M, Jiang W, McLendon RE, Pan E, Khasraw M, Walsh KM, Lu Y, Herlyn M, Mills G, Herbig U, Wei Z, Keir ST, Flaherty K, Liu L, Wu K, Shay JW, Abdullah K, Zhang G, Ashley DM. Yu S, et al. Among authors: herlyn m. Clin Cancer Res. 2021 Dec 15;27(24):6800-6814. doi: 10.1158/1078-0432.CCR-21-0374. Epub 2021 Sep 30. Clin Cancer Res. 2021. PMID: 34593527 Free PMC article.

2

Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck.

Sauter ER, Nesbit M, Watson JC, Klein-Szanto A, Litwin S, Herlyn M. Sauter ER, et al. Among authors: herlyn m. Clin Cancer Res. 1999 Apr;5(4):775-82. Clin Cancer Res. 1999. PMID: 10213212

3

Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas.

Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffetz S, Herlyn M. Sauter ER, et al. Among authors: herlyn m. Cancer Res. 1999 Oct 1;59(19):4876-81. Cancer Res. 1999. PMID: 10519399

4

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.

Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Smalley KS, et al. Among authors: herlyn m. Mol Cancer Ther. 2006 May;5(5):1136-44. doi: 10.1158/1535-7163.MCT-06-0084. Mol Cancer Ther. 2006. PMID: 16731745

5

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KS, Herlyn M, Morrissey MM, Tuveson DA, Huang PS. King AJ, et al. Among authors: herlyn m. Cancer Res. 2006 Dec 1;66(23):11100-5. doi: 10.1158/0008-5472.CAN-06-2554. Cancer Res. 2006. PMID: 17145850

6

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.

Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, Herlyn M. Smalley KS, et al. Among authors: herlyn m. Cancer Res. 2007 Jan 1;67(1):209-17. doi: 10.1158/0008-5472.CAN-06-1538. Cancer Res. 2007. PMID: 17210701

7

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.

Smalley KS, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA, Flaherty KT, Herlyn M. Smalley KS, et al. Among authors: herlyn m. Br J Cancer. 2007 Feb 12;96(3):445-9. doi: 10.1038/sj.bjc.6603596. Epub 2007 Jan 23. Br J Cancer. 2007. PMID: 17245336 Free PMC article.

8

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.

Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS. Haass NK, et al. Among authors: herlyn m. Clin Cancer Res. 2008 Jan 1;14(1):230-9. doi: 10.1158/1078-0432.CCR-07-1440. Clin Cancer Res. 2008. PMID: 18172275

9

Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.

Smalley KS, Contractor R, Nguyen TK, Xiao M, Edwards R, Muthusamy V, King AJ, Flaherty KT, Bosenberg M, Herlyn M, Nathanson KL. Smalley KS, et al. Among authors: herlyn m. Cancer Res. 2008 Jul 15;68(14):5743-52. doi: 10.1158/0008-5472.CAN-08-0235. Cancer Res. 2008. PMID: 18632627 Free PMC article.

10

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.

Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL. Smalley KS, et al. Among authors: herlyn m. Mol Cancer Ther. 2008 Sep;7(9):2876-83. doi: 10.1158/1535-7163.MCT-08-0431. Mol Cancer Ther. 2008. PMID: 18790768 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

676 results

Search Page